Pharmadrug (Pharmadrug) Common Stock : $24.76 Mil (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is Pharmadrug Common Stock?

Pharmadrug's quarterly common stock declined from Jun. 2023 ($23.50 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($24.76 Mil).

Pharmadrug's annual common stock declined from Dec. 2021 ($23.91 Mil) to Dec. 2022 ($22.98 Mil) but then increased from Dec. 2022 ($22.98 Mil) to Dec. 2023 ($24.76 Mil).

Pharmadrug Common Stock Historical Data

The historical data trend for Pharmadrug's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharmadrug Common Stock Chart

Pharmadrug Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

10.04

17.04

23.91

22.98

24.76

Pharmadrug Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															22.98	22.82	23.50	-	24.76

Pharmadrug Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Pharmadrug (Pharmadrug) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Pharmadrug Inc (OTCPK:LMLLF) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

G11:Germany PHRX:Canada

Address

77 King Street West, Suite 2905, Toronto, ON, CAN, M5K 1H1

Website

https://www.pharmadrug.ca

Pharmadrug Inc is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics and naturally derived approved drugs. The Company's operations comprise of the corporate division in Canada. Geographically, it operates in Germany and Canada.